Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Historical Data Period | 2021 - 2025 |
| Base Year Market Size (2026) | USD 114.59 Million |
| Market Size (2027) | USD 115.98 Million |
| Market Size (2032) | USD 121.69 Million |
| Growth Rate (2027 - 2032) | 1.21 % |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Europe Insulin Syringe Market Analysis by Mordor Intelligence
The Europe Insulin Syringe Market size is expected to increase from USD 114.59 million in 2026 to USD 115.98 million in 2027 and reach USD 121.69 million by 2032, growing at a CAGR of 1.21% over 2027-2032.
European countries are suffering from the burden of high diabetes expenditure due to its rising prevalence. In high-income countries, diabetes is one of the leading causes of cardiovascular diseases, blindness, kidney failure, and lower limb amputation. Technological advancements have increased over the period in Diabetes care devices for safer and more accurate administration of insulin. A needle and syringe are a common and cost-effective way for many people to take insulin. Approximately 10% of the total diabetes population is having type-1 diabetes and approximately out of this 10% of people only 80-90% use Insulin delivery devices but the usage of insulin is rising from time to time, even type-2 diabetes patients are using the insulin devices.
According to the IDF report, about 1 in 11 adults contain diabetes in Europe, accounting for approximately 61 million. These figures indicate that approximately 19.6% of global expenditure is spent on diabetes in Europe. Every year 21,600 children are added to the type-1 diabetic population pool. The European region witnessed an alarming increase in the prevalence of diabetes in recent years. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as oral anti-diabetic medication or ingestion of additional carbohydrates by monitoring their blood glucose levels.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Europe Insulin Syringe Market Trends and Insights
Increasing diabetes prevalence
The diabetes population in the European region is expected to rise by more than 5% over the forecast period.
The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of insulin. Type-1 diabetic patients must check their blood glucose levels regularly, monitor their blood glucose levels, and adjust the insulin dosing accordingly. Insulin syringes are designed for self-injection and offer a reliable solution for insulin injection. An insulin syringe is made of three parts, which consist of a needle, a barrel, and a plunger. Needles are usually short and thin to reduce the pain of injection.
Various initiatives by the Government, such as the National Service Framework (NSF) program in the United Kingdom, are improving services by setting national standards to drive up service quality and tackle variations in care. The Association of British HealthTech Industries launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind.
Therefore, owing to the factors above, the studied market is anticipated to grow over the analysis period.
Russia holds the highest market share in the Europe Insulin Syringe Market in the current year
Russia holds the highest market share of more than 51% in the Europe Insulin Syringe Market in the current year.
According to Roscongress, Russia ranks fifth in the world regarding the number of patients with diabetes mellitus aged 20 to 79. The World Health Assembly Resolution recommends the integration of prevention and treatment of diabetes into primary health services, developing pathways for a substantial increase in access to insulin, promoting convergence and harmonizing regulatory requirements for diabetes medicines and technologies, and improving diabetes monitoring and surveillance.
Furthermore, it involves the WHO advising the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.
The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among people are some market opportunities for the players.
Competitive Landscape
The Europe Insulin Syringe Market is moderately fragmented and driven by constant innovations by manufacturers such as Becton Dickinson, Terumo Corporation, and HMD Healthcare Ltd. It resorts to inorganic market strategies, such as mergers and acquisitions, to establish market dominance while adhering to organic growth strategies. It is evident from the R&D spending of these companies.
Europe Insulin Syringe Industry Leaders
-
Becton Dickinson
-
Terumo Corporation
-
B. Braun Medical Inc.
-
Nipro Corporation
-
HMD Healthcare Ltd.
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- November 2023: Terumo India launched new Insulin Syringe for diabetic patients who need daily injections to control their condition.
- October 2022: Becton, Dickinson, and Company and Biocorp signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay technology. It is a solution designed to capture and transmit injection events using Near Field Communication technology to the BD UltraSafe Plus Passive Needle Guard used with pre-fillable syringes.
- October 2022: Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation and manufacturer of primary container, injection, and infusion therapy devices, launched a ready-to-fill polymer syringe. The PLAJEX 2.25 mL with a tapered needle is specifically designed for challenging biotech products with a larger volume.
Europe Insulin Syringe Market Report Scope
Insulin syringes are used for self-injection and are available in multiple sizes to help deliver different insulin doses. The europe insulin syringe market is segmented into geography. The report offers the value (in USD) and volume (in units) for the above segments.
Geography
| United Kingdom |
| Germany |
| France |
| Russia |
| Spain |
| Italy |
| Rest of Europe |
| Geography | United Kingdom |
| Germany | |
| France | |
| Russia | |
| Spain | |
| Italy | |
| Rest of Europe |
Key Questions Answered in the Report
How big is the Europe Insulin Syringe Market?
The Europe Insulin Syringe Market size is expected to reach USD 115.98 million in 2027 and grow at a CAGR of 1.21% to reach USD 123.16 million by 2032.
What is the current Europe Insulin Syringe Market size?
In 2026, the Europe Insulin Syringe Market size is expected to reach USD 114.59 million.
Who are the key players in Europe Insulin Syringe Market?
Becton Dickinson, Terumo Corporation, B. Braun Medical Inc., Nipro Corporation and HMD Healthcare Ltd. are the major companies operating in the Europe Insulin Syringe Market.
What years does this Europe Insulin Syringe Market cover, and what was the market size in 2025?
In 2025, the Europe Insulin Syringe Market size was estimated at USD 113.22 million. The report covers the Europe Insulin Syringe Market historical market size for years: 2021, 2022, 2023, 2024, and 2025. The report also forecasts the Europe Insulin Syringe Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.